Featured
Search Clinical Trials
Completed
Ability to Cope With Type 1 Diabetes (External Link)
Coping with type 1 diabetes can be very difficult. Type 1 diabetes is a very unique chronic disease because it requires constant attention to several responsibilities such as daily glucose …
Baylor Role:
Lead Sponsor
Completed
Ability to Cope With Type 1 Diabetes (External Link)
Coping with type 1 diabetes can be very difficult. Type 1 diabetes is a very unique chronic disease because it requires constant attention to several responsibilities such as daily glucose …
Baylor Role:
Lead Sponsor
Completed
Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia (External Link)
BACKGROUND: HIV lipodystrophy syndrome is associated with both metabolic (e.g., dyslipidemia and insulin resistance) and anthropomorphic (e.g., lipoatrophy and central obesity) abnormalities. These defects are likely to predispose HIV patients …
Baylor Role:
Lead Sponsor
Completed
The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes (External Link)
The Diabetes Control and Complications Trial (DCCT) showed that improving blood sugar control for individuals with Type 1 diabetes (T1DM) stopped or delayed the onset of long-term complications. As a …
Baylor Role:
Lead Sponsor
Completed
The Role of Amylin and Glucagon in T1DM (External Link)
Objective: To develop a new treatment approach in the prevention of hypo and hyperglycemia in children with type 1diabetes. Background/Rationale: The diabetes control and complications trial (DCCT) showed that improving …
Baylor Role:
Lead Sponsor
Completed
Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome (External Link)
PROTOCOL OUTLINE: Participants are treated with subcutaneous leuprolide acetate followed by oral spironolactone. Each treatment is administered daily for 6 weeks, with a 6-week washout between drugs. Patients and controls …
Baylor Role:
Collaborator